Descovy or Truvada for Treatment Adherence

Phase-Based Progress Estimates
Fenway Health, Boston, MA
Treatment Adherence+4 More
Descovy or Truvada - Drug
What conditions do you have?

Study Summary

This trial is testing a new way to give people PrEP, the HIV prevention medication, to see if it helps them stay on the medication and if it has any side effects. Descovy or Truvada is used to treat Treatment Adherence. The treatment can be done online. No patients in this trial will receive a placebo. Descovy or Truvada has previously been approved by the FDA for a different condition.

Eligible Conditions

  • Treatment Adherence
  • Adherence, Medication
  • Substance Use
  • HIV Infections

Treatment Effectiveness

Effectiveness Progress

2 of 3
This is further along than 85% of similar trials

Study Objectives

2 Primary · 2 Secondary · Reporting Duration: After Month 2 Visit

After Month 2 Visit
Acceptability of DPS and Digital Phenotyping App
Correlation of PrEP Adherence with DBS Concentrations
Correlation of PrEP Adherence with Digital Phenotyping Patterns
PrEP Adherence Patterns

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Trial Design

1 Treatment Group

Digital Pills and Beiwe
1 of 1
Experimental Treatment

40 Total Participants · 1 Treatment Group

Primary Treatment: Descovy or Truvada · No Placebo Group · Phase 3

Digital Pills and BeiweExperimental Group · 3 Interventions: ID-Cap System, Descovy or Truvada, Beiwe · Intervention Types: Device, Drug, Device

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: after month 2 visit
Closest Location: Fenway Health · Boston, MA
Photo of Boston 1Photo of Boston 2Photo of Boston 3
2011First Recorded Clinical Trial
1 TrialsResearching Treatment Adherence
7 CompletedClinical Trials

Who is running the clinical trial?

Gilead SciencesIndustry Sponsor
999 Previous Clinical Trials
657,464 Total Patients Enrolled
Brigham and Women's HospitalOTHER
1,454 Previous Clinical Trials
9,700,840 Total Patients Enrolled
Fenway Community HealthLead Sponsor
30 Previous Clinical Trials
5,291,783 Total Patients Enrolled
Peter R Chai, MD MMSPrincipal InvestigatorBrigham and Women's Hopsital
1 Previous Clinical Trials
100 Total Patients Enrolled

Eligibility Criteria

Age 18+ · Male Participants · 8 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are a cisgender male.
You have sex with men.
For this criterion, a positive result for PrEP does not automatically equate to a positive result for HIV.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.